ADD-ONS
Cerebral hyperperfusion syndrome (CHS)
Created 04/11/2021, last revision 07/05/2023
-
Cerebral Hyperperfusion (reperfusion) Syndrome (CHS) can occur within hours to days after a revascularization procedure (carotid endarterectomy, carotid artery stenting, revascularization in moyamoya syndrome, severe aortic stenosis repair)
-
the peak incidence of CHS and hemorrhage after CEA is 5-7 days and 12-48 h after CAS [Ogasawara, 2007]
- longer delay (days to weeks) was reported as well
- CHS following aortic stenosis surgery may lead to bilateral lesions
-
- incidence 1-14% (usually approximately 7%) according to various authors
- CEA and CAS pose similar risks (Galyfos, 2017)
- incidence is higher in moyamoya surgery (Hayashi, 2012)
- most patients with CHS have mild symptoms and signs
- the cornerstone of prevention is strict perioperative BP correction (at least for 14-21 days)
Pathophysiology
Content available only for logged-in subscribers (registration will be available soon) |
Clinical presentation
- severe headache
- worsening in the prone position
- ipsilateral to the lesion side or diffuse
- impaired consciousness
- epileptic seizures (often focal)
- focal neurologic deficit (usually in ICH)
Diagnostic evaluation
Content available only for logged-in subscribers (registration will be available soon) |
Management
- rigorous blood pressure correction (ideally <120/85 mmHg) – it also serves as a prevention
-
in case of seizure activity, administer AE drugs (PHE, VPA, LEV) → acute symptomatic seizures
-
antiedema therapy
Management of patients with hemorrhagic transformation/SAH/ICH
- discontinue antiplatelet therapy, consider platelet concentrate infusion
-
administer SOLUMEDROL 25 mg IV. (to neutralize the effect of clopidogrel or other thienopyridines) [Qureshi, 2008]
-
if the CT scan indicates no progression in 24h, patients with stent should be given aspirin; postpone clopidogrel therapy for 5-7 days